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ABSTRACT 
 
In South Africa, the World Health Organisation estimated 454 000 new cases of 
Mycobacterium Tuberculosis (M.tb) infection (MTB) in 2015. Disseminated tuberculosis 
arises from haematogenous spread of the bacilli and seeding of the bacilli in extrapulmonary 
sites. The current gold standard for the detection of MTB of the bone marrow is TB culture 
which has an average turnaround time of 6 weeks. Although shorter, histological 
examinations of trephine biopsy cores to diagnose MTB also have a time delay owing mainly 
to the 5-7 day processing period prior to microscopic examination. Adding to the diagnostic 
delay is the non-specific nature of granulomatous inflammation which is the hallmark of 
MTB involvement of the bone marrow. A Ziehl-Neelson stain (which highlights acid-fast 
bacilli) is therefore mandatory to confirm the diagnosis but can take up to 3 days for 
processing and evaluation. Owing to this delay in diagnosis, many patients are lost to follow 
up or remain untreated for up to six weeks while the results are awaited, thus encouraging the 
spread of undiagnosed TB.  
The Xpert MTB/RIF (Cepheid, Sunnyvale, CA) is the molecular test used in the South 
African national TB program as the initial diagnostic test for pulmonary TB in adults and 
children. In 2013 the Xpert MTB/RIF was applied to diagnose extrapulmonary TB and 
despite being available in 207 testing sites nationwide, it was never investigated for its 
potential application in diagnosing TB in bone marrow. Therefore, this study investigates the 
optimisation and performance of Xpert MTB/RIF on bone marrow aspirate specimens. 
BMA specimens received for routine immunophenotypic analysis as part of the investigation 
into disseminated MTB or in the evaluation of cytopenias in immunocompromised patients 
were used in this study. Processing BMA on the Xpert® MTB/RIF was optimised to ensure 
bone marrow in EDTA and heparin did not inhibit the PCR reaction. Inactivated M.tb from an 
Xpert MTB/RIF external quality assessment program was spiked into the clinical bone 
marrow specimen and distilled water (as a control). A volume of 500µl and an incubation time 
of 15 minutes with sample reagent were investigated as the processing protocol. 
 
A total of 135 BMA specimens had sufficient residual volume for Xpert® MTB/RIF testing 
however 22 specimens (16.3%) were not included in the final statistical analysis as an adequate 
trephine biopsy and/or TB culture was not available. Xpert MTB/RIF testing was possible in 
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the presence of heparin or EDTA, but the overall detection of MTB in BMA was low compared 
to histology and culture.    
The sensitivity of the Xpert® MTB/RIF when compared to both histological and culture 
findings was 8.7% with a 95% confidence interval (CI) of 1.07-28.04%. The sensitivity of the 
Xpert® MTB/RIF compared to histological findings only was 11.1% with a 95% CI of 1.38-
34.7%. The specificity of the Xpert® MTB/RIF was 98.9% (95% CI: 93.9-99.7%). 
 
Although the Xpert® MTB/RIF has a shorter turnaround time than histology and TB culture 
and is less expensive than culture and drug susceptibility testing, the low sensitivity of the 
Xpert® MTB/RIF in this study limits its current use for the diagnosis of MTB in bone marrow 
aspirate specimens until the diagnostic algorithm or the assay is further defined.    
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CHAPTER 1: INTRODUCTION 
1.1  HISTORY AND CHARACTERISTICS OF MYCOBACTERIA 
 
The genus Mycobacterium is hypothesised to have emerged more than 150 million years ago 
however Hermann Heinrich Robert Koch was the first to identify the tubercle bacillus 
(Mycobacterium tuberculosis(M.tb)) and postulate its infectious nature in humans in 1882 (1, 
2). The M.tb bacilli are rod-shaped, non-spore forming, aerobic organisms spread by airborne 
droplets (3). They are classified as acid-fast bacilli owing to their ability to retain the colour of 
arylmethane dyes when exposed to dilute mineral acid (4). The lipid cell wall of the bacillus is 
comprised of mycolic acid attached to a polysaccharide arabinogalactan and has many integral 
roles which include providing resistance to antibiotics and influencing the growth rate of the 
organism (5). As the organism replicates, it acquires mutations within its genome as a result of 
random DNA transcriptional errors. This allows for phenotypic variation between infections 
such as sensitivity to drugs, interaction with the host immune cells and the ability to 
disseminate to other tissues such as bone marrow (4).  
 
The term MOTT (Mycobacterium Other Than Tuberculosis (TB)) was used when subsequent 
studies identified the organism in other species. This includes M. avium (avian) and M. bovis 
(bovine) (4). 
1.2 PATHOPHYSIOLOGY 
 
Once inhaled, most of the bacilli are trapped in the upper airways in close proximity to the 
goblet cells. These cells serve as the first line of defence owing to their mucus producing 
properties and are sufficient for the prevention of full-blown infection in healthy individuals 
(6, 7). Those bacilli that are capable of evading the goblet cells reach the alveoli and are 
phagocytosed by macrophages. This is enhanced by the binding of complement protein C3 to 
the bacterial cell wall (opsonisation). Despite being engulfed by alveolar macrophages, the 
bacilli continue multiplying at a rate of one cell division every 25-32 hours (6). The cytokines 
released from the macrophages recruit T lymphocytes thus shifting the immune response from 
an initial innate mediated to a cell mediated response. This process can take 2-12 weeks (8).  
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In an immunocompetent host, granulomatous inflammation occurs around the bacillus as the 
next step in containing the infection. Granulomas are predominantly comprised of T 
lymphocytes and macrophages and are characterised by low pH levels, low oxygen content and 
limited nutrients. These areas then undergo fibrosis and calcification resulting in a latent 
bacillus contained within a healed lesion (9). In immunocompromised patients, the inability of 
the immune system to contain the primary infection leads to symptomatic pulmonary disease. 
In addition, the formation of a granuloma is usually unsuccessful with early breakdown and 
extradition of the material into a blood vessel. This allows for haematogenous dissemination 
of the bacilli to extrapulmonary sites (9).  
1.2.1 M.tb INFECTION (MTB) IN THE HIV POSITIVE POPULATION 
 
Human Immunodeficiency Virus (HIV) is the biggest risk factor for acquiring M.tb infection 
(MTB) which in turn is the leading cause of death in people with HIV (10). As mentioned 
above, cell mediated immunity plays a vital role in the initial containment of MTB. This is 
driven by CD4+ T cells and is therefore compromised in HIV where the hallmark of disease is 
the steady depletion of CD4+ T cells. Other mechanisms that contribute to increased 
susceptibility to MTB (both primary and reactivation/post primary disease) include impaired 
tumour necrosis factor (TNF)-mediated macrophage apoptotic response to the bacillus (11), 
up-regulation of receptors on macrophages facilitating MTB entry (12) and impaired 
chemotaxis (13). 
 
The TB-HIV relationship is a mutually beneficial one as M.tb increases the expression of CCR5 
and CXCR4 receptors on CD4+ T cells which are known entry points for the HIV virus (14). 
Replication of the HIV virus is increased and has been demonstrated at sites of MTB infection 
in the lung and within macrophages and lymphocytes of the pleural space (15, 16). This is 
reflected in vivo by the rising viral loads noted in patients with both infections. Increased viral 
replication occurs as a bystander effect when TNF is secreted by T lymphocytes with the 
primary aim to inhibit M.tb growth (17).  M.tb can directly stimulate TNF production through 
a component of its cell wall, lipoarabinomannan. This occurs via the NF-κB pathway which 
leads to the transcriptional activation of the long terminal repeat promotor thus enhancing HIV 
replication (18). 
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The diagnosis of MTB in a HIV positive person is challenging given the frequency of smear 
negative cases, the unusual/atypical presentations and the lack of granuloma formation on 
histological specimens. A high index of suspicion is required as well as novel diagnostic 
methods to shift the focus away from acid-fast bacilli detection in the diagnosis of active TB. 
Latent MTB infection (LMTBI) is described as an entity in which there is no manifestation of 
disease and M.tb cannot be cultured however clinical suspicion of infection exists (19). 
Identifying LMTBI is beneficial as it allows for an early diagnosis in individuals at high risk 
for transformation to active MTB (such as the immunocompromised). This can be done via 
two methods - the tuberculin skin test and interferon gamma release assays. Whilst much 
information is available regarding these tests, LMTBI is not the focus of this study.  
1.3 EPIDEMIOLOGY 
1.3.1 GLOBAL PERSPECTIVE OF MTB 
 
In 2015, there were approximately 10.4 million new cases of MTB globally with a male to 
female ratio of 1.5:1. South Africa was one of six countries that accounted for 60% of these 
new cases (Figure 1). Despite this seemingly large number, the World Health Organisation 
(WHO) reports a decline in MTB incidence at a rate of 1.5% from 2014 to 2015. Deaths owing 
to MTB were estimated at 1.4 million in 2015 with MTB retaining its position as one of the top 
ten causes of death worldwide (20). 
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Figure 1: Global incidence of TB for 2015 (20) 
 
New cases of multidrug-resistant TB (MDR-TB; defined as resistance to, at least, rifampicin 
and isoniazid) were estimated at 480 000 in 2015 with 100 000 new cases of rifampicin 
resistant TB (20).  
 
Africa and particularly Southern Africa accounted for the highest percentage of HIV and MTB 
co-infection however only 81% of patients notified for MTB had a documented HIV result 
implying that the burden of co-infection may be higher (20) (Figure 2).  
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Figure 2: Estimated HIV prevalence of new and relapsed TB cases in 2015 (20) 
1.3.2 MTB AND HIV IN SOUTH AFRICA 
 
MTB in South Africa is rife in poorer socio-economic environments making MTB 
identification, control and reporting a challenge (21). 
 
The WHO Global TB Report 2016 reported 454 000 new cases of MTB in South Africa of 
which 56% were co-infected with HIV(20).  Data regarding incidence (reported as rate per 
100 000 population) from 2000 – 2015 is represented graphically in Figure 3 and shows an 
initial upward growth but a decline after 2005. From 2014 however, the total incidence appears 
to have stabilised. 
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Figure 3: MTB incidence in South Africa from 2000 – 2015 (20) 
 
Overall mortality from MTB amounted to 98 000 cases with a fatality ratio of 0.22 (0.1-0.42). 
The majority (~74%) occurred in the HIV positive population with a mortality rate of 133 per 
100 000. These statistics are similar to the previous year (22).  
 
In 2015, MTB accounted for 0.4 million deaths in the HIV positive population (20). Of the new 
and relapsed cases of MTB in 2015 in South Africa, 57% were positive for HIV. Of these, 85% 
were on anti-retroviral treatment (ART). Whilst this appears impressive, it is not in line with 
the WHO recommendation that all HIV positive people with MTB infection should receive 
ART (23). This recommendation by the WHO is supported by a study performed in South 
Africa which showed that by increasing the ART roll-out, the incidence of confirmed 
pulmonary MTB declined over a period of four years (2008-2012) (24). 
1.4 EXTRAPULMONARY MTB 
 
Extrapulmonary MTB infection (EPTB) is defined as MTB outside of the pulmonary system 
and occurs as a result of seeding of the M.tb bacilli via haematogenous, lymphoid or mucosal 
routes. If two or more non-contiguous sites are involved, the term disseminated TB (synonym: 
miliary TB) is used. EPTB is more common in those with advanced HIV as the associated 
immunosuppression allows for rapid progression of the disease following 
exposure/reactivation of the organism (4).  
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In South Africa, as per the WHO Global TB report 2016, EPTB cases accounted for 10% 
(20). Further specification regarding the site involved was not included in this report however 
a study performed locally (at the National Health Laboratory Services (NHLS) 
Mycobacteriology Referral Laboratory in Johannesburg) revealed the most common 
extrapulmonary specimens received for TB culture. These are cerebrospinal fluid, fine needle 
aspirates (predominantly from lymph nodes) and serous effusions (pleural or ascitic) (Table 
1). In this study, the prevalence of EPTB was 23% (277 of 1,175 specimens tested) (25).  
 
Table 1: Extrapulmonary specimens received for TB culture (in  
order of frequency). Table adapted from (25). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.5 DISSEMINATED MTB INVOLVING THE BONE MARROW 
 
Bone marrow involvement by the M.tb bacilli occurs as a result of haematogenous spread and 
can present with specific haematology findings (such as cytopenias), pyrexia of unknown 
origin and/or non-specific constitutional symptoms (fever, night sweats and loss of weight) 
(26). In an 18 month period at Chris Hani Baragwanath Academic Hospital, south of 
Johannesburg, 15% of the bone marrow aspirates and trephines received were for suspected 
disseminated TB. Over half of these cases had unexplained cytopenias (27). A study conducted 
in 2010 in India concluded that bone marrow examinations are highly useful in HIV positive 
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patients presenting with pyrexia of unknown origin (PUO) as MTB was the commonest cause 
of PUO, accounting for 60% of all cases in this study (28).  
Disseminated TB with bone marrow involvement requires ~9 months of treatment (comparable 
to other extra pulmonary sites) with the same drugs used for pulmonary TB. There is however 
a higher mortality rate among patients with bone marrow TB involvement when compared to 
other sites (29). For these reasons, if clinical suspicion of disseminated TB involving the bone 
marrow exists (e.g. the presence of cytopenias), a bone marrow aspirate and trephine biopsy 
with material for TB culture is indicated.  
1.5.1 CURRENT DIAGNOSTIC PRACTICES FOR DISSEMINATED TB 
INVOLVING THE BONE MARROW 
 
When a bone marrow procedure is performed as part of the investigation of disseminated 
mycobacterial infection, three components are essential. These are outlined in Figure 4 and 
explained in detail in the text that follows. Of note, three pathology disciplines are involved in 
the processing and diagnosis of MTB. This includes haematology (analyses bone marrow 
aspirate smears and trephine biopsies), microbiology (processes TB cultures) and anatomical 
pathology (processes the trephine biopsies and performs the Ziehl-Neelson (ZN) stain).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Outline of the components involved in the diagnosis of MTB in bone marrow as 
followed by the NHLS 
 
Bone marrow trephine biopsy Bone marrow aspirate  
Smears TB culture  Assessed for granulomatous 
inflammation 
ZN stain ordered by attending 
pathologist 
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1) Bone marrow (BM) aspirate slides are fixed in 10% methanol and stained twice with 
Giemsa’s stain. Examination usually reveals reactive features which are non-diagnostic. 
The slides can be stained with auramine O for the identification of acid fast bacilli using 
fluorescent microscopy however this is not commonly done as a study performed locally 
revealed an overall low yield of positive cases using this method (7 of 123 cases) (27).  
2) Bone marrow trephine biopsies undergo 24 hours of formalin fixation followed by a 
minimum of 48 hours decalcification in ethylenediaminetetraacetic acid (EDTA) disodium 
salt. The specimen is then embedded into moulds, cut and stained with haematoxylin and 
phloxine. 
 
As mentioned previously, the hallmark of MTB is granulomatous inflammation. This is 
however non-specific and seen with several other infections (including cryptococcus), 
sarcoidosis, Hodgkin and Non-Hodgkin Lymphoma (30). As a result, a ZN stain is 
mandatory for confirmation of MTB. In our setting, this stain is performed only at the 
request of the attending pathologist. Due to the large amounts of lipid (mycolic acid) in the 
cell wall of the mycobacterium, traditional staining methods such as the Gram stain are 
ineffective. The ZN stain utilises heated carbolfuchsin to break through this lipid capsule. 
Initially, all viable cells stain with carbolfuchsin however after a process of acid and alcohol 
decolourisation only cells with the protective lipid layer retain the carbolfuchsin dye. 
Mycobacteria are thus acid and alcohol fast. The specimen is then stained with methylene 
blue which is taken up by non-acid fast organisms. Acid-fast bacilli (AFB) retain the pink 
colour of carbolfuchsin (31). 
 
From the description above, it is easy to see that this method of diagnosing MTB in the bone 
marrow can be protracted, taking on average 4-7 days to reach the pathologist.  In addition, the 
diagnostic yield of bone marrow trephine examinations is influenced by poor quality specimens 
(owing to clinician inexperience, degree of bone marrow infiltration or patient factors. The 
latter may include obesity, pelvic bed sores or fractures that interfere with obtaining a good 
quality, diagnostic specimen), differential sampling and paucibacillary specimens (that may 
appear negative for AFB on a ZN stain). 
 
3) TB culture and drug susceptibility analysis is the gold standard for detection of 
disseminated MTB. Myco-F lytic culture vials are required with a minimum of 5ml of bone 
marrow sample. This is incubated in the Bactec 9240 automated system with weekly 
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inspections for six weeks. If growth is detected, a smear is prepared from the TB culture 
bottle containing the bone marrow aspirate specimen and a ZN stain performed. One of the 
following scenarios can then occur (outlined in Figure 5 below): 
a. Only contaminating bacteria are identified and the ZN stain is negative for AFB. 
No further testing is performed in this scenario. 
b. Both AFB and contaminating bacteria are not identified. This implies a false 
positive flag by the instrument and the sample is re-incubated.  
c. If the ZN stain is positive for AFB regardless of the presence of contaminating 
bacteria, a rapid antigen test (the TB Ag MPT64 Rapid) is performed. This test 
identifies M.tb therefore if negative, polymerase chain reaction (PCR; specifically 
the Hain Genotype Mycobacterium CM, Hain Lifescience, Germany) is performed 
to identify the presence of MOTT. If the rapid antigen test is positive and drug 
susceptibility has been requested by the clinician, a subculture into a Mycobacteria 
Growth Indicator Tube (MGIT) is performed which is followed by a line probe 
assay (the MTBDRplus, Hain Lifescience, Germany) to identify susceptibility to 
the first line anti-TB agents, rifampicin and isoniazid.  
 
The protracted nature of this TB culture leads to delayed diagnosis of the disease with the 
knock on effect of losing patients to follow up and hindering TB infection control.  
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Figure 5: Schematic representation of the processing of bone marrow Bactec Myco-F Lytic 
culture in the TB reference laboratory of NHLS 
Incubate Myco-F Lytic culture bottle in BD Bactec 9240 instrument for 42 
days 
Growth detected 
 ZN stain performed 
No growth detected 
Negative result 
ZN positive for AFBs 
with/without 
contaminating bacteria 
Rapid antigen test 
(TB Ag MPT64 Raid)  
MTBDRplus (a first line line probe assay) performed for the 
confirmation of MTB and identification of RIF and/or INH 
resistance 
MTB confirmed 
No AFBs and no 
contaminating 
bacteria 
PCR (Hain Genotype Mycobacterium 
CM) performed for the identification 
of MOTT 
BD Bactec Myco-F Lytic liquid culture 
bottle received in laboratory 
Re-incubate 
No AFBs, 
contaminating 
bacteria only 
No further testing 
Positive Negative 
Subculture into a MGIT tube which 
is placed into a MGIT 960 
instrument 
 
If drug susceptibility requested, a 
subculture into a MGIT tube is 
performed which is placed into a 
MGIT 960 instrument 
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1.6 OTHER DIAGNOSTIC METHODS FOR TB 
1.6.1 WHO ENDORSED TECHNOLOGIES  
1.6.1.1 XPERT® MTB/RIF 
 
The Xpert® MTB/RIF assay from Cepheid (Sunnyvale, California) is a cartridge based assay 
using hemi-nested real time PCR to amplify the rpoB gene which is specific to M.tb. In 
addition, the Xpert® MTB/RIF assay is capable of simultaneously detecting resistance to the 
most commonly used first line anti-TB drug, rifampicin (RIF).   
 
The assay utilises five probes (A-E; also known as molecular beacons) which are 
complementary to overlapping regions of the rpoB gene (Figure 6) and the 81 base pair RIF 
Resistance Determining Region (RRDR) which is the site of mutation for more than 95% of 
all RIF resistant strains (32).   
 
 
Figure 6: The 81bp RRDR of the rpoB gene showing the overlapping molecular probes (33) 
 
Each probe is allocated a specific fluorescent marker. When unhybridised, the probes do not 
fluoresce as the quencher and the fluorescent dye are in close proximity. This is enabled by the 
curved conformation of the probes. Once hybridised to the RRDR region, the probe flattens 
out and the quencher no longer suppresses the fluorescent dye. An increase in fluorescence 
above the background is reported by the software as a positive result.  A positive result for the 
presence of M.tb is deemed if two or more probes emit a signal within two cycles of each other 
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(34).  If there is resistance to RIF, hybridisation of the probe will not occur as there is a change 
in sequence in the RRDR region of the rpoB gene owing to the mutation/s present (34). As a 
result, a fluorescent signal will not be released. Resistance to RIF is therefore identified by the 
lack of a detectable cycle threshold for a specific probe or if the difference in cycle threshold 
between the first and last rpoB signals is >4.1.  If <4.1, a result of rifampicin sensitive is 
reported.  
 
Included in the cartridge is a Sample Processing Control (SPC) which is a separate PCR 
reaction (but occurs simultaneously to the sample PCR reaction) and assesses for the presence 
of Bacillus globigii spores (34). This serves as an internal control and allows for the verification 
of the integrity and effectiveness of processing.  
 
The Xpert® MTB/RIF is fully automated but does require the addition of a reagent buffer to 
liquefy and inactivate any M.tb bacilli present in the specimen. The limit of detection for the 
Xpert® MTB/RIF is 150 cfu/mL (34) however with the advent of the Xpert® MTB/RIF Ultra 
(Cepheid), this may be improved upon (35). This latest assay utilises a new cartridge that allows 
for double the amount of sample DNA (as compared to the Xpert® MTB/RIF) to be used in 
the PCR reaction. The five original probes described above are replaced with four probes which 
detect mutation in the rpoB gene as well as real-time probes that target the IS6110 and 
IS1081genes of M.tb. Whilst being as easy to use, this new assay has a 10x lower limit of 
detection compared to the original Xpert® MTB/RIF and can detect a wider variety of rpoB 
gene mutations (36). As of March 2017, the WHO recommends the use of Xpert® MTB/RIF 
Ultra as a replacement assay for the current Xpert® MTB/RIF (37). 
 
The steps involved in the Xpert® MTB/RIF assay are shown in Figure 7 (38). 
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Figure 7: Components of Xpert® MTB/RIF assay. Adapted from (38). 
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The results are interpreted using the algorithm shown in Figure 8 (33):  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Interpretation of results as reported by the Xpert® MTB/RIF test (33) 
 
 
 
Check probe 
Fail Pass Result: Error 
Two or more rpoB gene probes hybridise 
No Yes 
All 5 probes 
hybridise 
1/more probes do not 
hybridise or show 
delayed hybridisation 
with a difference in 
cycle threshold of 
>4.1  
Result:  
 M.tb detected 
 RIF resistance 
not detected 
Result:  
 M.tb detected 
 RIF resistance 
detected 
Internal control 
positive  
Internal control 
negative 
Result:  
 Invalid 
Result:  
 M.tb not 
detected 
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In the instances where M.tb is detected, the instrument reports levels of M.tb DNA in the sample 
by analysis of the cycle thresholds (Ct). Based on an average of the Ct values of all five probes, 
a lower Ct denotes a higher DNA concentration and a higher Ct denotes a lower DNA 
concentration (Table 2) (21, 33).  
       Table 2: The reported MTB result based on the Ct range 
 
 
 
 
 
The 2013 WHO policy update for the use of the Xpert® MTB/RIF assay on pulmonary 
specimens was based on 27 studies with more than 9000 participants. A meta-analysis of these 
studies revealed the following (39):  
 As an initial diagnostic test used instead of smear microscopy, the Xpert® MTB/RIF 
assay had a pooled sensitivity of 88% (95% CI: 84–92%) and a pooled specificity of 
99% (95% CI: 98– 99%). 
 If performed after a negative smear-microscopy result, the Xpert® MTB/RIF had a 
pooled sensitivity of 68% (95% CI: 61–74%) and a pooled specificity of 99% (95% CI: 
98–99%). 
 For smear-positive culture-positive MTB, the pooled sensitivity of the Xpert® 
MTB/RIF was 98% (95% CI: 97–99%). 
 In the HIV positive population, the pooled sensitivity of Xpert® MTB/RIF was 79% 
(95% CI: 70–86%). 
 In the HIV negative population, the pooled sensitivity was 86% (95% CI: 76–92%). 
 When used to identify RIF resistance, Xpert® MTB/RIF resulted in a pooled sensitivity 
of 95% (95% CI: 90–97%) and a pooled specificity of 98% (95% CI: 97–99%).  
 
Based on the above findings, the WHO strongly recommends the use of Xpert® MTB/RIF in 
place of conventional testing (microscopy, culture and drug susceptibility testing) as the initial 
diagnostic test in both adults and children suspected of having MDR-TB or HIV-associated 
Result 
 
Ct range 
High <16 
Medium 16-22 
Low 22-28 
Very low >28 
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TB. A conditional recommendation (acknowledging resource constraints) is also included 
whereby the Xpert® MTB/RIF can be used instead of the conventional testing mentioned 
above as the initial diagnostic test in children and adults suspected of having pulmonary TB. It 
can also be used as a follow-up test to microscopy (especially if smear negative) in adults 
suspected of having pulmonary TB if they are not at risk of MDR-TB or HIV-associated TB. 
 
The use of Xpert® MTB/RIF assay on pulmonary specimens in South Africa commenced in 
March 2011 following WHO recommendations and is used in the National TB programme as 
the initial diagnostic tool for diagnosing MTB. In 2017, evidence 5 years post implementation 
showed a decline in the TB notification rate in both the HIV positive (19% decrease) and HIV 
negative (12% decrease) populations since the advent of the rollout. A positive Xpert® 
MTB/RIF result also surpassed a positive microscopy result as the number one reason for 
commencing TB treatment. This shows how well clinicians have taken to this relatively new 
assay in our setting (40).  
 
The results of the meta-analysis performed by the WHO in determining the sensitivity and 
specificity of the Xpert® MTB/RIF in diagnosing EPTB is summarised in Table 3.  
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Table 3: A meta-analysis of the sensitivity and specificity of the Xpert® MTB/RIF in 
diagnosing EPTB at the commonest sites involved (39). 
 
Sample type  Pooled sensitivity (95% 
confidence interval) 
Pooled specificity (95% 
confidence interval) 
 
Lymph node  84.9% (72-92%) 
 
 92.5% (80-97%) 
 
Cerebro-spinal fluid  79.5% (62-90%) when 
compared against culture 
 55.5% (51-81%) when 
compared against a 
composite reference 
standard 
 
 98.6% (96-100%) 
 
 98.8% (95-100%) 
Pleural fluid  43.7% (25-65%) when 
compared against culture 
 17% (8-34%) when 
compared to a composite 
reference standard 
 
 98.1% (95-99%) 
 
 99.9% (94-100%) 
 
Overall, pleural fluid is a poor specimen for the diagnosis of MTB however if Xpert® 
MTB/RIF is positive, this should be considered evidence of disease and treated as such (39).  
A study performed locally demonstrated the sensitivity of the Xpert® MTB/RIF in comparison 
to liquid culture for various specimen types (including pulmonary and extrapulmonary 
specimens) (41).  This is shown in Figure 9. 
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Figure 9:  A radar plot of the sensitivity of the Xpert® MTB/RIF compared to liquid culture 
for various specimen types and including performance among the HIV+ population. Adapted 
from (41). 
 
It is evident that the sensitivity of the Xpert® MTB/RIF is higher with pulmonary samples (and 
especially so with smear positive specimens) compared to the extrapulmonary samples 
assessed. Lymph node tissue/aspirate in the HIV positive population is the exception noted in 
the local study.   
 
Owing to limited availability, data on the use of the assay on bone marrow aspirate (BMA) 
specimens was omitted from the WHO systematic review and meta-analysis. Often, these 
specimens are included with other extra-pulmonary specimens and an overall assessment of 
the performance of the Xpert® MTB/RIF assay is reported. The findings of some of the studies 
that included BMA samples are shown in Table 4.  
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Table 4: Studies utilising bone marrow aspirate specimens on the Xpert® MTB/RIF  
 
Authors: No. of BMA 
specimens/total specimens 
(%)  
 
Sensitivity: Specificity: 
 
Armand et al (42) 
 
 
6/37 (16.2%) 
 
53% 
 
- 
 
Malbruny et al (43) 
 
 
2/89 (2.2%) 
 
85.7% 
 
97.3% 
 
Clemente et al (44) 
 
 
1/72 (1.4%) 
 
73.6% 
 
99.9% 
 
Kim et al (45) 
 
 
11/1540 (0.7%) 
 
67.7% 
 
98.1% 
 
Moure et al (46) 
 
 
1/149 (0.7%) 
 
58.3% 
 
100% 
 
The 2013 WHO policy recommendations regarding the use of the Xpert® MTB/RIF assay for 
extra pulmonary specimens (with the exception of blood, urine and stool) is summarised below 
(39). 
 
 Strong recommendations: 
o If TB meningitis is suspected, CSF specimens should be processed first on the 
Xpert® MTB/RIF instead of conventional testing (microscopy, culture and drug 
sensitivity testing). 
 Conditional recommendations (acknowledging resource constraints): 
o For certain non-respiratory specimens, the Xpert® MTB/RIF can be used instead 
of conventional practices for the diagnosis of EPTB. This includes lymph node 
specimens. 
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Although the Xpert® MTB/RIF has a broad global footprint and has been highly successful 
(especially in the diagnosis of pulmonary TB), there are other technologies endorsed by the 
WHO which can be used together with or instead of the Xpert® MTB/RIF. The main 
characteristics of these tests are highlighted in Table 5. 
1.6.1.2 LINE PROBE ASSAYS 
 
Line probe assays (LPAs) are strip-based tests that utilise PCR and reverse hybridisation 
methods to amplify DNA. In addition to identifying the presence of M.tb, these assays also 
detect genotypic susceptibility to RIF and isoniazid (INH) by identifying mutations in three 
genes - rpoB, katG and inhA genes (47).  
 
As noted above, the 81 base pair region of the rpoB gene is the commonest site for mutations 
that confer resistance to rifampicin. Similarly, 80-90% of all INH resistant strains can be 
localised to mutations within the katG and inhA genes (47).  
 
Figure 10 shows an outline of the steps involved in this assay (48): 
 
DNA extraction from the specimen  
 
The target gene is amplified using PCR and biotinylated primers 
 
The PCR products are hybridised to specific oligonucleotide probes located on a strip  
 
Hybridisation is visually observed by the presence of coloured bands at the site of probe 
binding. This signals the presence of M.tb as well as wild-type rpoB, katG and inhA genes 
 
Figure 10: Flow diagram demonstrating the processing of specimens using LPAs 
 
If a genetic mutation is present in one or more of the target genes, the PCR products will not 
hybridise with the wild type probes but will bind to the specific probes for the commonly 
occurring mutations.  
 
Advantages of this type of technology include: 
 Able to be performed directly on sputum or other specimens  
 Detects INH resistance 
 Rapid turnaround time (TAT) when compared to culture 
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Disadvantages include: 
 Longer time to result (when compared to Xpert® MTB/RIF) 
 Personnel trained in PCR are required  
 Regional/centralised laboratory set-up required 
 
Based on the two first-generation assays (INNO-LiPARif.TB assay (Innogenetics, Ghent, 
Belgium) and Genotype MTBDR assay (HainLifescience GmbH, Nehren, Germany), the 
WHO approved the use of line probe assays for the diagnosis of MTB and identification of RIF 
resistance in smear positive cases in 2008 (48). The use of these first generation LPAs for smear 
negative specimens is not recommended by the WHO, a statement supported by the findings 
of a recent meta-analysis which showed a 50% difference in sensitivity between smear positive 
cases (89.4-99.4%) and smear negative cases (20.2-71.7%) (49). 
 
Since 2008, the pioneering LPAs are no longer in use however newer versions have been 
developed. A meta-analysis commissioned by the WHO evaluated 74 studies which looked at 
three of these new technologies (Hain Genotype MTBDRplusV1, MTBDRplusV2 and Nipro 
NTM+MDRTB). This revealed a pooled sensitivity of 96.7% (95% CI: 95.6-97.5%) and 
pooled specificity of 98.8% (95% CI: 98.2-99.2%) with regards to the detection of RIF 
resistance. INH resistance had a pooled sensitivity of 90.2% (95% CI: 88.2–91.9%) and a 
pooled specificity of 99.2% (95% CI: 98.7–99.5%) (49).  
 
LPAs for the detection of resistance to the commonly used second line anti-MTB therapy 
(termed second-line line probe assays or SL-LPA) utilises probes within the gyrA, rrs and gyrB 
genes as well as the eis promoter to identify resistance to fluroquinolones or the injectable 
agents.  These assays are recommended by the WHO for patients with confirmed rifampicin-
resistant or multidrug-resistant MTB as the initial test for the identification of resistance to 
fluroquinolones (50).  
1.6.1.3 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION ASSAY 
 
Loop-mediated isothermal amplification (LAMP) was described by Notomi et al as a DNA 
amplification method using a DNA polymerase with strand displacement activity, four  primers 
which recognise six sites on the target gene and a constant temperature (~65°C) (51). 
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Subsequently, the technique has been modified to increase the effectiveness and reduce the 
turnaround time of the test (52, 53).  
 
A meta-analysis performed in 2016 revealed a pooled sensitivity of 93% (95% CI: 92-95%) 
and a pooled specificity of 94% (95% CI: 92-95%)(54). 
 
The advantages of this assay include (55): 
 Temperature independent amplification of DNA 
 Rapid TAT (requires less than an hour to perform) 
 Simple to perform and requires minimal laboratory equipment – therefore can be used 
at peripheral healthcare centres 
 Safe – similar biosafety requirements as those for sputum smear microscopy 
 Easy to read as the endpoint depends on degree of turbidity which is analysed visually 
under ultraviolet light 
 
Currently, the WHO recommends (on condition) the use of the TB-LAMP assay in adults as a 
replacement or add-on test for smear microscopy for the diagnosis of pulmonary TB if the signs 
and symptoms are consistent with TB (56). 
 
As this assay is incapable of detecting rifampicin resistance, the Xpert® MTB/RIF remains the 
first choice. However, if the Xpert® MTB/RIF cannot be implemented (for example in places 
with poor electrical supply, poor temperature control, excessive humidity and/or excessive 
dust), the TB-LAMP assay can be considered as an alternative (56).  
1.6.1.4 LIPOARIBINOMANNAN ASSAY  
 
Lipoaribinomannan (LAM) is a 17-19kDa lipopolysaccharide found in the cell wall of M.tb 
microbes and account for 15-18% of the total weight of the bacteria. It is secreted into urine 
during active MTB infection and is therefore an accessible antigen to assay. Previously, 
enzyme-linked immunosorbent assays (ELISA) formed the basis of LAM diagnostic testing 
however these are not feasible in a resource limited setting. Hence, a lateral flow version of the 
assay (LF-LAM) has been developed as a qualitative point of care test (57). 
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The commercially available kit is the Determine™ TB LAM Ag (shown in Figure 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Test strip and reference card of the Determine™ TB LAM Ag kit (57) 
 
A small amount of urine (60µL) is placed onto the sample pad of the test strip and incubated 
at room temperature for 25-35 minutes. Provided the control band is present, the patient’s result 
can be accepted. This is facilitated by the provision of a reference card to which the band 
intensity can be compared.  
 
A study performed in South Africa by Peter et al evaluated the Determine™ TB LAM among 
hospital inpatients. Various methods were used to assess the sensitivity which varied between 
45% and 71% (58). A meta-analysis performed by the WHO revealed a pooled sensitivity of 
44% (95% CI: 31-60%) and a pooled specificity of 92% (95% CI: 83-96%). 
As of 2015, the WHO recommends the LF-LAM assay in HIV positive hospitalised patients 
with signs and symptoms of pulmonary TB or EPTB and a CD4 count less than or equal to 100 
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cells/µL. This assay is also recommended in patients who are unable to produce sputum or in 
seriously ill HIV positive people regardless of CD4 count (definition of seriously ill: 
tachypnoea of >30 breaths/minute, temperature >39ºC, tachycardia >120 beats/minute and/or 
inability to walk unaided). There is a strong recommendation that this assay should not be used 
as a screening tool (59). 
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Table 5: Summary of the WHO endorsed technologies 
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1.6.2 TESTS UNDER EVALUATION 
1.6.2.1 REALTIME MTB AND REALTIME MTB-INH/RIF ASSAYS 
 
The RealTime MTB assay from Abbott Molecular (Des Plaines, Illinois) is a novel nucleic acid 
amplification test (NAAT) utilising real time PCR to qualitatively detect M.tb in pulmonary 
specimens (60). It is fully automated and has a higher throughput compared to the original 
Xpert® MTB/RIF (capable of processing 94 specimens per batch). This test amplifies two 
genes of M.tb namely protein antigen B (paB) and the multicopy insertion element IS6110 for 
the detection of MTB infection. In addition, the Abbott RealTime MTB-INH/RIF resistance 
assay allows for the detection of drug resistance in positive specimens. Whilst this does not 
occur simultaneously like in the Xpert® MTB/RIF assay, it does allow for the detection of 
resistance against INH which the Xpert® MTB/RIF assay does not. Similar to the line probe 
assays, the RealTime MTB INH/RIF resistance assay identifies mutations in the katG and inhA 
genes for INH resistance and in the rpoB gene for resistance to rifampicin.  A study conducted 
by Hofmann-Thiel et al. revealed an overall sensitivity of the assay in pulmonary samples of 
92.1% (95% CI: 87.9-95.1%) with a lower sensitivity noted in smear negative samples 
compared to smear-positive cases (76.2% vs 100% respectively). This sensitivity was 
comparable in extrapulmonary samples. The specificity of this assay was shown to be 99.6% 
(95% CI: 98.3-99.9%) and with regards to identification of resistance, there was a 99.5% 
agreement between the RealTime MTB-INH/RIF resistance assay and the genotypic and 
phenotypic manifestations. A local study included HIV positive patients and found a sensitivity 
of 82.5% (CI: 67.2-92.7%) and specificity of 93.1% (CI: 86.2-97.2) on raw sputum when 
compared to liquid culture. If the sputum was concentrated prior to processing, the sensitivity 
declined by 5% whilst the specificity improved by 2%.  
Studies are ongoing using this platform in the diagnosis of MTB but so far demonstrate positive 
findings and certain definite advantages over the Xpert® MTB/RIF assay (60, 61). As it is 
widely used for HIV viral load testing, it offers the opportunity to integrate multiple tests on a 
single platform. 
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1.7 OBJECTIVES OF THIS MMED RESEARCH REPORT 
 
 
In the current South African landscape, the Xpert® MTB/RIF is improving patient care 
through the rapid diagnosis of MTB. However, an area where data is lacking is the diagnostic 
utility of the Xpert® MTB/RIF in bone marrow aspirate specimens. As shown previously, as 
part of the investigation into disseminated TB involving the bone marrow, three modalities 
are performed – bone marrow aspirate smear, trephine biopsy and TB culture. The last two 
tests are associated with a substantial delay in diagnosis. If the Xpert® MTB/RIF is 
performed at the same time as these other modalities, a reportable result could be obtained 
within 24 hours allowing timeous initiation of treatment. As all three modalities require 
processing by different pathology departments, the Xpert® MTB/RIF could assist in 
integrating these disciplines.  
 
The primary objectives of this study were therefore:   
a) To assess the ability of the Xpert® MTB/RIF assay to identify MTB in anticoagulated 
bone marrow aspirate specimens 
b) To evaluate the sensitivity and specificity of the Xpert® MTB/RIF compared to the gold 
standard histological testing, liquid culture and drug susceptibility assays in BMA 
specimens.  
Secondary objective: 
a) To investigate the utility of the Xpert® MTB/RIF using BMA specimens as part of the 
diagnostic algorithm of MTB in a high prevalence TB and HIV setting. 
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CHAPTER 2: MATERIALS AND METHODS 
2.1 SPECIMEN SELECTION  
 
BMA specimens collected as part of the investigation for disseminated TB or for the 
investigation of cytopenias in immunocompromised patients and sent for routine 
immunophenotypic analysis at the NHLS flow cytometry laboratory in Charlotte Maxeke 
Johannesburg Academic Hospital (CMJAH) between July 2015 and October 2015 were used 
in this study. BMA specimens for immunophenotypic analysis are routinely collected in EDTA 
and heparinised tubes. An aliquot of each sample (0.5-1ml) was collected prior to 
immunophenotypic analysis to prevent possible interference from immunophenotypic 
processing (e.g. isolating cells by the Ficol method or the addition of phosphate buffer 
solution). A maximum of 1ml of specimen was utilised as this was found to be the most 
common volume available for testing that would still allow for adequate cell numbers for 
immunophenotypic analysis. The longest time delay between collection and processing of the 
specimens in this study was 3 days and is attributed to the weekend when the flow cytometry 
laboratory is closed. The same specimen selection criteria were used for the Xpert® MTB/RIF 
test optimisation and the performance evaluation arms of the study. 
 
Ethical approval was obtained from the University of the Witwatersrand Human Research 
Ethics Committee (M09-06-88; Appendix 3).  
2.2 OPTIMISATION OF THE XPERT® MTB/RIF FOR BONE MARROW 
ASPIRATE SPECIMENS 
2.2.1 ASSESSMENT FOR PCR INHIBITORS IN BMA AND TO ASSESS THE 
APPROPRIATE SPECIMEN VOLUME 
 
To establish if BMA contains inhibitors to the Xpert® MTB/RIF PCR reaction and to assess 
test performance using varying volumes of bone marrow, the following were processed (and 
repeated five times on the same sample): 
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1) 1ml heparinised BMA specimens with 25µL of inactivated M.tb.  
2) 500µl heparinised BMA specimens with 25µL of inactivated M.tb 
3) 500µl heparinised BMA specimens with serial dilutions of inactivated M.tb (ranging 
from 5µl to 25µl). 
2.2.2 ASSESSMENT OF THE EFFECT OF ANTICOAGULANTS ON THE XPERT® 
MTB/RIF PCR REACTION 
 
The following were performed and repeated five times on the same sample: 
 
1) 500µL BMA specimens from EDTA tubes with 25µL of inactivated M.tb. 
 
2) From the same patient, 500µL BMA specimens from EDTA tubes and 500µL BMA 
specimens from heparinised tubes with 25µL of inactivated M.tb. 
2.2.3 DISTILLED WATER AS A CONTROL:  
 
1) 500µL distilled water with 25µL of inactivated M.tb. 
2) 500µL distilled water with serial dilutions of inactivated M.tb (ranging from 5µl to 
25µl).  
 
2.3 SAMPLE PROCESSING 
Sample-reagent (SR) buffer was added to the specimens to obtain a 2ml volume of 
sample/buffer mixture (minimum required for Xpert® MTB/RIF processing (38)). These 
mixtures were spiked with inactivated rifampicin sensitive M.tb that is used as dried culture 
spots as part of the Xpert® MTB/RIF external quality assurance programme (62)  to ensure a 
known quantity of detectable M.tb in the clinical specimen.  The mixtures were incubated for 
a minimum of 15 minutes at room temperature as per the manufacturer’s guidelines. The 
sample/SR buffer mixture was then transferred into the GeneXpert cartridges and inserted into 
the instrument.  
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In addition, distilled water was processed in the same way to assess for differences in results 
that could be attributed to the inhibition of the Xpert® MTB/RIF PCR reaction by BMA and/or 
the anticoagulant. 
 
The Ct of the sample processing control was documented to ensure validity of the results. In 
addition, the CT of each probe was documented to assess for possible inhibition to the reaction.  
2.4 EVALUATION OF THE XPERT ® MTB/RIF FOR THE DETECTION 
OF M.tb IN PATIENT BMA SPECIMENS 
 
On the basis of the results of the optimization study, the evaluation arm of the study 
commenced using 500µL of patient specimens from both EDTA and heparinised tubes. This 
was added to SR buffer in a 1:3 ratio and incubated for 15 minutes at room temperature prior 
to transfer into the cartridge. The cartridges were immediately inserted into the GeneXpert 
instrument. The ratio of specimen to buffer differs from the manufacturer’s guidelines (Figure 
7) and was based on obtaining the total minimum sample/buffer mixture (2ml) required for 
processing.  
2.5 DATA COLLECTION 
 
The Laboratory Information System (LIS) was used to obtain minimal information on each 
specimen (Appendix 1). This included the HIV status of the patient from which the specimen 
was obtained as well as the results of the TB culture and trephine biopsy to which the Xpert® 
MTB/RIF result was compared. The Ct of each probe was documented as this correlates to the 
amount of M.tb DNA present in the specimen and the result reported by the instrument (see 
Table 2).  
2.6 EXCLUSION CRITERIA 
 Specimens with no corresponding trephine biopsy or TB culture result were not 
included in the final statistical analysis. 
 Insufficient specimens at the time of receipt (<1ml) were excluded to allow for 
adequate cell numbers for immunophenotyping. 
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2.7 STATISTICS 
Statistical analysis was performed using the MedCalc Statistical Software programme (Ostend, 
Belgium) (25). Sensitivity and specificity as well as the positive and negative predictive values 
were calculated using the number of true positive, true negative, false positive and false 
negative results. The likelihood ratios were calculated using the sensitivity and specificity: 
 Positive likelihood ratio = sensitivity/(100-specificity) 
 Negative likelihood ratio = (100-sensitivity)/specificity 
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CHAPTER 3: RESULTS 
 
3.1 SPECIMENS PROCESSED 
BMA specimens obtained for this study: 
 Optimisation phase: 
o Five BMA specimens, each of which was analysed five times  
o EDTA and heparinised BMA specimen from the same patient (each analysed in 
triplicate) 
 Evaluation phase: 
o 135 BMA specimens were analysed. Of these: 
 11 specimens were specifically submitted by the requesting clinican for 
the exclusion of TB involving the bone marrow  
 The remainder (124 specimens) were chosen as the request form 
indicated the presence of both HIV and cytopenias in the patient. 
3.2 OPTIMISATION OF THE XPERT® MTB/RIF FOR BMA 
SPECIMENS 
3.2.1 ASSESSMENT FOR PCR INHIBITORS IN BMA AND TO ASSESS THE 
APPROPRIATE SPECIMEN VOLUME 
 
Table 6: Results using 1ml heparinised BMA specimens with 25µL of inactivated M.tb in 
a single sample run in quintuplicate.  
*MTB, Mycobacterium tuberculosis; RIF, rifampicin; QC, quality control; Ct, cycle 
threshold; SPC, sample processing control 
 
Test MTB status RIF status Internal QC 
status 
Ct of probes SPC Ct 
I Detected – low Susceptible Passed 24.5-26.2 26.8 
 
II Detected – low Susceptible Passed 25.0-26.9 30.2 
 
III Detected – medium 
 
Susceptible Passed 18.4-20.4 26.7 
 
IV Detected – medium 
 
Susceptible Passed 18.3-20.3 29.9 
V Detected – high Susceptible Passed 15.0-17.0 25.6 
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Table 7: Results using 500µL heparinised BMA specimens with 25µL of inactivated M.tb 
in a single sample run in quintuplicate.  
 
 
These results demonstrate that a minimum of 500µL BMA specimen is sufficient to generate a 
result using the Xpert® MTB/RIF assay. The results are overall comparable to a higher volume 
of specimen (1ml) as low and medium results are obtained and the specific Ct values appear to 
overlap. There is however a single “very low” result seen with the fourth repeat of 500µL of 
specimen and a “high” result is seen with the fifth repeat of 1ml of specimen, which suggests 
imperfect reproducibility in Xpert® MTB/RIF results. As the performance between the 2 tested 
sample volumes was similar, a sample volume of 500µL was opted for the evaluation arm of 
this study as it allowed for a higher residual volume for immunophenotypic processing. Going 
forward, using a lower specimen volume is also helpful in the cases of difficult BM aspirations 
when the amount of specimen obtained can be limited.   
 
 
 
 
 
Test MTB status RIF status Internal QC 
status 
Ct of probes SPC Ct 
I Detected – medium 
 
Susceptible Passed 18.2-20.2 27.0 
II Detected – low Susceptible Passed 22.2-23.9 27.7 
 
III Detected – medium 
 
Susceptible Passed 19.1-20.8 25.7 
IV Detected – very low 
 
Susceptible Passed 33.0-35.3 28.2 
V Detected – medium 
 
Susceptible Passed 20.7-22.5 28.0 
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3.2.2 ASSESSMENT OF THE EFFECT OF ANTICOAGULANTS ON THE XPERT® 
MTB/RIF PCR REACTION 
 
Table 8: Results using 500µL BMA specimens obtained from ETDA tubes with 25µL of 
inactivated M.tb added in a single sample run in quintuplicate.  
 
 
Table 9: Results of 500µL BMA specimens obtained from the same patient and from 
EDTA and heparinised tubes run in triplicate for each anticoagulant. 25µL of inactivated 
M.tb added.  
 
 
Test MTB status RIF status Internal 
QC status 
Ct of probes SPC Ct 
I Detected – high 
 
Susceptible Passed 13.7-15.6 25.2 
II Detected – medium 
 
Susceptible Passed 16.3-17.9 25.5 
III Detected – high 
 
Susceptible Passed 15.9-17.6 26.0 
IV Detected – medium 
 
Susceptible Passed 21.9-23.8 29.0 
V Detected – medium 
 
Susceptible Passed 17.2-19.2 26.5 
Test MTB status RIF status Internal 
QC status 
Ct of 
probes 
SPC Ct 
EDTA Detected – medium 
 
Susceptible Passed 21.5-23.3 24.9 
EDTA Detected – medium 
 
Susceptible Passed 21.9-23.7 24.4 
EDTA Detected – low 
 
Susceptible Passed 24.2-25.8 26.2 
HEPARIN Detected – medium 
 
Susceptible Passed 19.2-20.8 25.6 
HEPARIN Detected – medium 
 
Susceptible Passed 21.5-23.2 24.1 
HEPARIN Detected – medium 
 
Susceptible Passed 21.2-23.0 27.0 
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The analysis performed with the same BMA specimen showed comparable results for both of 
the common anticoagulant tubes (EDTA and heparin). This is helpful as these tubes are widely 
available and should the Xpert® MTB/RIF test be implemented for BMA specimens, it would 
be easy for the clinicians to submit an extra tube for processing.  
3.2.3. DISTILLED WATER AS A CONTROL: 
 
Table 10: Results using 500µl heparinised BMA specimens with serial dilutions of 
inactivated M.tb (ranging from 5µl to 25µl).  
 
 
Table 11: Results using 500µL distilled water with 25µL of inactivated M.tb in a single 
sample run in quintuplicate.  
 
 
 
 
 
 
Test MTB status RIF status Internal 
QC status 
Ct of probes SPC Ct 
25µL Detected – low 
 
Susceptible Passed 26.3-28.1 25.2 
20µL Detected – low 
 
Susceptible Passed 25.6-27.6 27.0 
15µL Detected- medium 
 
Susceptible Passed 20.4-22.2 25.2 
10µL Detected – medium 
 
Susceptible Passed 21.5-23.5 27.1 
5µL Detected – low 
 
Susceptible Passed 25.2-27.1 25.2 
Test MTB status RIF status Internal QC 
status 
Ct of probes SPC Ct 
I Detected – high 
 
Susceptible Passed 15.7-17.7 26.8 
II Detected – high 
 
Susceptible Passed 14.3-16.2 28.1 
III Detected – high 
 
Susceptible Passed 14.5-16.5 27.0 
IV Detected – high 
 
Susceptible Passed 13.9-16.2 26.5 
V Detected – high Susceptible Passed 14.5-16.6 25.7 
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Table 12: Results using 500µL distilled water and serial dilutions of inactivated M.tb.  
 
 
As expected, the spiked specimens generated a positive result for the detection of M.tb however 
when the Ct values were analysed to provide a semi-quantitative assessment of the M.tb 
concentration in the specimen, the “high” MTB status was seen predominantly with distilled 
water. The BMA specimens ranged from low to high with a prominence of low and medium 
results. This implies that BMA or heparin partially inhibits the PCR reaction but not enough to 
prevent the generation of a result. When serial dilutions of inactivated M.tb were utilised, 
distilled water demonstrated the expected response with a decline in MTB status with the lower 
concentrations. Interestingly, when BMA specimens were used under the same conditions, a 
“medium” MTB status was reported with 10µL and 15µL of inactivated M.tb yet a “low” result 
was seen with higher concentrations. The reason for this is unclear but it would be of value to 
assess if the viscosity of the specimens influenced the result. As the presence of M.tb was not 
excluded in the specimen prior to processing, it is possible that the “medium” MTB status noted 
with the lower concentrations could be attributed to the M.tb bacilli already present in the 
specimen.  
In summary, the results demonstrated the following: 
 500µL of BMA material (clinical specimen) incubated with SR buffer in a 1:3 ratio for 
15 minutes does not meaningfully inhibit the PCR reaction of the Xpert® MTB/RIF 
assay.  
 Results are comparable between heparin and EDTA anticoagulated specimens however 
the higher Ct value seen with the anticoagulated specimens (compared to distilled 
water) may indicate partial PCR interference. 
Test MTB status RIF status Internal 
QC status 
Ct of probes SPC Ct 
25µL Detected – high 
 
Sensitive Passed 14.4-16.4 25.7 
20µL Detected – high 
 
Sensitive Passed 15.6-17.3 27.2 
15µL Detected – high 
 
Sensitive Passed 15.5-17.3 25.7 
10µL Detected – medium 
 
Sensitive Passed 16.6-18 24.6 
5µL Detected – medium 
 
Sensitive Passed 19.3-20.8 27.2 
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3.3 EVALUATING THE XPERT® MTB/RIF ON BMA SPECIMENS 
 
Figures 12 and 13 outline the results obtained in this study. During the study period at the 
CMJAH NHLS flow cytometry laboratory, 135 bone marrow aspirate specimens had sufficient 
residual volume for Xpert® MTB/RIF testing. Of these, 85.2% (115/135) had a corresponding 
adequate trephine biopsy and/or had a TB culture submitted. Two (1.5%) had an inadequate 
trephine biopsy and although a TB culture was submitted, this was reported as contaminated. 
Therefore, in total, 16.3% (22/135) of the specimens were not included in the final statistical 
analysis. The prevalence of HIV seropositivity in this study was 85.9% (116/135). 
 
Granulomatous inflammation was seen on the trephine biopsy in 15.9% (18/113) of the 
specimens, half of which had a positive Ziehl-Neelson (ZN) stain. Five of these 18 specimens 
had a confirmatory positive result on TB culture (four of which already had a positive ZN stain) 
and six were negative on TB culture. Seven of the 18 positive results could not be confirmed 
as the TB culture was either not done or contaminated.   
 
A positive culture result was shown in 8.8% (10/113) with M.tb identified in 8 (species 
identification was not possible in two specimens). All 10 of these positive cases were negative 
on the Xpert® MTB/RIF and only half showed concordance with histology. Time to positivity 
of these cases ranged from 1-27 days with a median of 18 days. 
 
Xpert® MTB/RIF positivity was detected in four specimens, one of which had an inadequate 
trephine biopsy and a contaminated TB culture therefore this specimen was excluded from the 
final statistical analysis. Positivity on the Xpert® MTB/RIF was therefore shown in 2.7% 
(3/113) of the specimens. Two of these positive results concurred with the histological finding 
of AFB positive granulomas however in both instances the TB culture results were negative. 
One positive result failed to correlate with either the TB culture or the trephine biopsy. Two of 
the four cases resulted in a “very low M.tb detection” whilst the other two had a “low M.tb 
detection” result (Table 13). None of the four positive cases on the Xpert® MTB/RIF showed 
RIF resistance.  
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3.3 INCONCLUSIVE RESULTS  
 
The Xpert® MTB/RIF error rate was 1.5% (2/135) and these specimens were not repeated. In 
both instances, a cartridge error (error code 5007) was reported as the probe check value was 
below the minimum. This can be linked to sample viscosity, incorrect volume, improperly 
filled reaction tube or if the probe integrity has been compromised (see Appendix 2).  
There was a 12.4% (14/113) contamination rate on culture and all of these specimens produced 
a result on the Xpert® MTB/RIF (one positive result and 13 negative results). Twelve of the 
14 specimens had a corresponding adequate trephine biopsy, two did not. 
 
Figures 12 and 13 summarises the results obtained in this study. Of note, histology and TB 
culture shared five positive results however the total positive cases of each modality is 
included.  
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Figure 12: Flow diagram of the results obtained 
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biopsies and/or TB Bactec was not 
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MTB/RIF 
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Xpert® 
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n=2 
Xpert® 
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positive 
n = 0 
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on 
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Table 13:  Positive Xpert® MTB/RIF results in this study 
 
 
 
Case 
 
 
Correlating with 
histology/culture 
 
 
MTB 
Result  
 
RIF Result 
 
Ct* of probes 
 
Ct of SPC* 
 
1 
 
 
Yes (histology) 
 
Low  
 
Not 
detected 
 
Probe A – 24.7 
Probe B – 25.5 
Probe C – 25.2 
Probe D – 25.7 
Probe E – 26.5 
 
 
 
 
 
25.7 
 
2 
 
 
Yes (histology) 
 
Very low  
 
Not 
detected 
 
Probe A – 29.2 
Probe B – 29.3 
Probe C – 28.8 
Probe D – 29.7 
Probe E – 30.9 
 
 
 
 
 
25.3 
 
3 
 
No 
 
Low 
 
Not 
detected 
 
Probe A – 26.9 
Probe B – 27.6 
Probe C – 27.0 
Probe D – 28.1 
Probe E – 28.8 
 
 
 
 
 
24.6 
 
4 
 
Unknown 
 
 
Very low 
 
Not 
detected 
 
Probe A – 31.7 
Probe B – 30.9 
Probe C – 31.6 
Probe D – 31.7 
Probe E – 33.6 
 
 
 
25.1 
*Ct, cycle threshold; SPC, sample processing control. 
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Figure 13 describes the separate performance of histology, TB culture and the Xpert® 
MTB/RIF in this study. The latter confers the shortest time to reportable result but had the 
fewest positive results. Overall, histology reported the most number of positive cases. TB 
culture has the highest number of “no results” as it was either not performed by the clinician 
or was contaminated.  
 
 
 
 
*No result owing to inadequate/contaminated specimens, test not done or error code reported 
by Xpert® MTB/RIF instrument 
Figure 13: 100% stacked bar graph depicting MTB results for each diagnostic modality used 
in this study 
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3.4 CALCULATION OF SENSITIVITY AND SPECIFICITY 
 
The overall prevalence of MTB in this study based on the positive TB culture and histology 
results was 20.4% (23/113). Table 14 summaries the findings that follow. The sensitivity of 
the Xpert® MTB/RIF when compared to both histological and culture findings was 8.7% with 
a 95% confidence interval (CI) of 1.07-28.04%. The sensitivity improves when the Xpert® 
MTB/RIF is compared to histological findings only (11.1% with a 95% CI of 1.38-34.7%). The 
specificity of the Xpert® MTB/RIF was 98.9% (95% CI: 93.9-99.7%). The positive predictive 
value of the Xpert® MTB/RIF assay in bone marrow aspirate specimens was found to be 66.7% 
(95% CI: 15.93-95.48) with a positive likelihood ratio of 7.7. The negative predictive value of 
the Xpert® MTB/RIF assay for bone marrow aspirate specimens was 80.7% (95% CI: 78.66-
82.65%) with a negative likelihood ratio of 0.92 (25).  
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Table 14: Summary of statistical analysis of Xpert® MTB/RIF assay on bone marrow 
aspirate specimens 
 
 
 Xpert® MTB/RIF assay 
(%) 
95% Confidence Interval 
Sensitivity 
 Histology and culture 
 Histology only 
 
 
8.7% 
11.1%  
 
1.07-28.04% 
1.38-34.7% 
Specificity 
 
98.9% 93.9-99.7% 
Positive predictive value 
 
66.7% 15.93-95.48% 
Positive likelihood ratio 
 
7.7%  
Negative predictive value 
 
80.7% 78.66-82.65% 
Negative likelihood ratio 
 
0.92  
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CHAPTER 4: DISCUSSION 
 
This study evaluated the performance of the Xpert® MTB/RIF in bone marrow specimens 
submitted to the CMJAH immunophenotyping laboratory in Johannesburg, South Africa as 
part of the investigation of disseminated TB or to assess the cause/s of cytopenias in 
immunocompromised patients. The initial optimisation stage of the study showed that: 
 
 500µL of BMA material (clinical specimen) incubated with SR buffer in a 1:3 ratio for 
15 minutes does not meaningfully inhibit the PCR reaction of the Xpert® MTB/RIF 
assay.  
 Results are comparable between heparin and EDTA anticoagulated specimens however 
the higher Ct value seen with the anticoagulated specimens (compared to distilled 
water) may indicate partial PCR interference. 
 
These findings support the feasibility of Xpert® MTB/RIF testing on bone marrow aspirate 
specimens. 
 
The second arm of this study assessed the sensitivity and specificity of the Xpert® MTB/RIF 
assay in comparison to the current diagnostic practices (i.e. TB culture (employing Myco-F 
Lytic culture vials) and histological assessment of the trephine biopsy) in 113 bone marrow 
specimens. This showed the sensitivity of the Xpert® MTB/RIF assay was 8.7% (95% CI: 
1.07-28.04%). The two specimens in which the TB culture failed to identify a species may have 
been non-tuberculous mycobacteria which the Xpert® MTB/RIF would not have detected. The 
sensitivity improved when the Xpert® MTB/RIF was compared to histological findings only 
(11.1% with a 95% CI of 1.38-34.7%). When compared to other studies utilising 
extrapulmonary specimens, the sensitivity obtained in this study is lower. Possible reasons for 
this include paucibacillary specimens (this is supported by the high Ct values demonstrated in 
the positive specimens) and may be compounded by the low volume of specimen used. In 
addition, bone marrow as a specimen type and/or the presence of anticoagulants may interfere 
with the Xpert® MTB/RIF PCR reaction and result in a higher Ct. This may hamper detection 
of the bacilli particularly in instances where the bacterial load is already low. Studies performed 
previously to evaluate the sensitivity and specificity of the Xpert® MTB/RIF assay on 
extrapulmonary specimens did not often include bone marrow aspirate specimens. When they 
did, an overall assessment of the sensitivity and specificity was reported with no information 
46 
 
pertaining to bone marrow aspirate specimens specifically (42, 43, 45). In these cases, the 
sensitivity of the Xpert® MTB/RIF assay may be skewed especially if certain specimens (such 
as CSF and lymph node) are included in the study as the assay has already been shown to have 
a higher sensitivity with these specimens (39). A meaningful comparison between studies 
regarding the sensitivity of the Xpert® MTB/RIF assay on bone marrow aspirate specimens is 
therefore not possible owing to the limited data available.  
 
The specificity of the Xpert® MTB/RIF assay in this study was shown to be 98.9% (95% CI: 
93.9-99.7%). This correlates well with other studies performed on extrapulmonary specimens.  
 
The last objective of this study was to develop a protocol to include the Xpert® MTB/RIF 
assay in the processing of bone marrow aspirate specimens to diagnose or exclude MTB 
infection. As mentioned above, the specimens were collected at the flow cytometry laboratory 
of CMJAH. Whilst this is a quaternary hospital, the Xpert® MTB/RIF instrument is compact 
and does not require a Biosafety Level 3 laboratory. It can therefore be used at the peripheral 
hospital performing the bone marrow investigation.   This will reduce the need for specimen 
transportation, reduce the number of lost specimens and will allow same-day results. When 
performing a bone marrow investigation, material is aspirated for immunophenotypic analysis. 
Similarly, a small amount of material can be aspirated and placed into a separate heparin or 
EDTA tube for Xpert® MTB/RIF testing. The specimen will then be processed as per the 
manufacturer’s guidelines and as determined in this study.  
 
This study shows that a separate bone marrow aspirate specimen could be submitted for 
processing on the Xpert® MTB/RIF as it will generate a faster result than histology and TB 
culture. The assay is less expensive than culture and drug sensitivity testing (63) however the 
low sensitivity of the Xpert® MTB/RIF in this study warrants alternative methods (see 
recommendations in section 4.2) to improve the sensitivity before introducing the assay into 
the diagnostic algorithm for the identification of MTB in bone marrow. Negative Xpert® 
MTB/RIF results do not necessarily exclude disease but may be related to a low bacterial 
burden in the specimen. This observation can be compared to the lower sensitivity of the 
Xpert® MTB/RIF assay noted in smear negative pulmonary cases.  
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Limitations to this study are: 
 Only a limited number of specimens were tested with the final number included in the 
analysis further reduced as an adequate corresponding trephine biopsy and/or TB 
culture was not available.  
 Owing to the small volume of specimen used, paucibacillary specimens may have 
resulted in false negative results.  
 
It would be of benefit to expand on this study to assess if a higher volume of BMA specimen 
may have improved the outcome and resulted in a better detection of MTB using the Xpert® 
MTB/RIF.  
 
This study used 15 minutes as the incubation time for the sample/SR buffer mixture as per the 
manufacturer’s guidelines. It would however be of interest to assess if an increased exposure 
to the SR buffer would improve the sensitivity of the assay. It is postulated that this longer time 
prior to processing may allow macrophages to release the ingested bacilli.  
 
With the recent recommendation by the WHO (37), assessment of the sensitivity of the Xpert® 
MTB/RIF Ultra assay to diagnose MTB in bone marrow would be a valuable study considering 
the improved sensitivity of this assay particularly in paucibacillary and extrapulmonary 
specimens.  
4.1 CONCLUSION 
 
Although the Xpert® MTB/RIF has a shorter turnaround time than histology and TB culture 
and is less expensive than culture and drug susceptibility testing, the low sensitivity of the 
Xpert® MTB/RIF in this study limits its current use for the diagnosis of MTB in bone marrow 
aspirate specimens until the diagnostic algorithm or the assay is further defined.    
Alternative methods (such as the Xpert® MTB/RIF Ultra assay, longer incubation times and/or 
higher volume of BM specimens) are warranted to further optimise the assay. Negative Xpert® 
MTB/RIF results do not necessarily exclude disease but may be related to a low bacterial 
burden in the specimen. More sensitive TB diagnostic tools such as the Xpert® MTB/RIF Ultra 
assay warrant re-evaluation of the clinical and diagnostic algorithms for patient care. Although 
TB culture remains the gold standard for the detection of M.tb in bone marrow aspirate 
specimens, it is limiting in its time to diagnosis and clinical relevance.  
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APPENDIX  
 
APPENDIX 1: PATIENT INFORMATION OBTAINED FROM LIS (LABORATORY 
INFORMATION SYSTEM) 
 
 Laboratory number 
 Referral hospital 
 Hospital number 
 Date of collection 
 History as per the bone marrow request form 
 Latest Full Blood Count and Differential Count 
 Bone marrow aspirate findings 
 Bone marrow trephine biopsy findings 
 Ziehl-Neelson result 
 TB Bactec result 
 Other Xpert® MTB/RIF assays performed – results and type of sample 
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APPENDIX 2: XPERT® MTB/RIF ERROR CODES 
 
 
 
Invalid 
 
Internal control has failed. PCR reaction was inhibited.  
 
 
5006/5007/5008 
 
Probe check control has failed. Can be linked to sample viscosity, 
incorrect volume, reaction tube is improperly filled or probe integrity 
is compromised 
 
 
2008 
 
Pressure exceeds the maximum pressure allowed or Xpert® MTB/RIF 
module failure. Usually a random error linked to sample viscosity 
 
 
No result 
 
Insufficient data was collected as the test has failed to run to 
completion. 
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APPENDIX 3: ETHICS CLEARANCE 
 
 
 
 
 
56 
 
 
APPENDIX 4: SUPERVISOR LETTER & TURN-IT-IN REPORT 
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